Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00523380
First received: August 30, 2007
Last updated: February 28, 2017
Last verified: February 2017
  Purpose
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of rIL-21 and Caelyx in cancer patients who have relapsed after, or have persistent disease after, first line therapy. Patients will be treated for 6 months.

Condition Intervention Phase
Cancer
Ovarian Cancer
Drug: recombinant interleukin-21
Drug: caelyx (pegylated liposomal doxorubicin)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: An Open-Label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients With Persistent or Progressive Disease After, or Relapse Within One Year of, Completion of Standard First Line Therapy

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Efficacy of treatment assessed by overall response rate (RR). RR measured and recorded using imaging techniques, CA-125 blood samples and pelvic examination. [ Time Frame: after max. 6 treatment cycles ]

Secondary Outcome Measures:
  • Pharmacokinetics [ Time Frame: Initially ]
  • IL-21 antibody formation [ Time Frame: For the duration of the trial ]
  • Progression free survival [ Time Frame: For the duration of the trial ]
  • Patient reported outcomes [ Time Frame: For the duration of the trial ]
  • Biomarker assessments CA-125 [ Time Frame: For the duration of the trial ]

Enrollment: 10
Actual Study Start Date: October 4, 2007
Study Completion Date: January 7, 2009
Primary Completion Date: January 7, 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: recombinant interleukin-21
Administered i.v. in treatment cycles of 28 days.
Other Names:
  • rIL-21
  • NN028
Drug: caelyx (pegylated liposomal doxorubicin)
Administered i.v. in treatment cycles of 28 days.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced epithelial Ovarian Cancer (stage IIB-IV)
  • Persistent or progressive disease after or relapse within one year of completion of first line therapy
  • Measurable or assessable disease
  • Eastern Cooperative Oncology Group status less than or equal to 2

Exclusion Criteria:

  • History of any other active malignancy
  • Signs of CNS metastasis
  • More than one prior chemotherapy regimen
  • Radiotherapy (bone) less than 4 weeks prior to start of treatment and radiotherapy (visceral) less than 8 weeks
  • First line chemotherapy completed at least 1 month prior to start of treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00523380

Locations
France
Novo Nordisk Investigational Site
Lyon Cedex 08, France, 69373
Novo Nordisk Investigational Site
Marseille, France, 13273
Novo Nordisk Investigational Site
Saint-Herblain Cedex, France, 44805
Novo Nordisk Investigational Site
Villejuif, France, 94805
Germany
Novo Nordisk Investigational Site
Essen, Germany, 45122
Novo Nordisk Investigational Site
Marburg, Germany, 35043
Novo Nordisk Investigational Site
Wiesbaden, Germany, 65199
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00523380     History of Changes
Other Study ID Numbers: NN028-1802
2007-001506-25 ( EudraCT Number )
Study First Received: August 30, 2007
Last Updated: February 28, 2017

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Doxorubicin
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 25, 2017